Business
Rani Therapeutics Reports Second Quarter 2025 Financial Results; Provides Corporate Update
– Announced strategic research collaboration with Chugai for two undisclosed molecules – – Presented preclinical data demonstrating bioequivalence of novel, bispecific GLP-1/GLP-2 receptor agonist delivered orally via RaniPill (RT-114) compared to subcutaneous delivery at ENDO 2025 – – Phase 1 study for RT-114 for the treatment of obesity expected to initiate in the second half of 2025 – – Announced a warrant inducement transaction with an existing investor with gross proceeds of $4.3 million –
About this update from Chugai Pharmaceutical Co., Ltd.
[{"type":"image","alt":"Rani Therapeutics, LLC","displaySize":"","headline":null,"caption":"Rani Therapeutics, LLC","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":150,"url":"https://media.zenfs.com/en/globenewswire.com/eedd36d474bbaf8ede890d5712b0f73a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/XWNAoYI1bIyf8QCPVkOpHw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIxMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/eedd36d474bbaf8ede890d5712b0f73a","width":300,"height":150}},"lazy":false},{"type":"text","content":"– Announced strategic research collaboration with Chugai for two undisclosed molecules –","length":88,"tagName":"p"},{"type":"text","content":"– Presented preclinical data demonstrating bioequivalence of novel, bispecific GLP-1/GLP-2 receptor agonist delivered orally via RaniPill (RT-114) compared to subcutaneous delivery at ENDO 2025 –","length":195,"tagName":"p"},{"type":"text","content":"– Phase 1 study for RT-114 for the treatment of obesity expected to initiate in the second half of 2025 –","length":105,"tagName":"p"},{"type":"text","content":"– Announced a warrant inducement transaction with an existing investor with gross proceeds of $4.3 million – ","length":108,"tagName":"p"},{"type":"text","content":"– Announced pricing of $3.0 million registered direct offering – ","length":64,"tagName":"p"},{"type":"text","content":"SAN JOSE, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today reported financial results for the second quarter ended June 30, 2025 and provided a corporate update.","length":335,"tagName":"p"},{"type":"text","content":"“In the second quarter of 2025, we have announced a research collaboration with Chugai for two molecules with undisclosed targets,” said Talat Imran, Chief Executive Officer of Rani Therapeutics. “We believe this collaboration has the potential to transform into a long-term strategic partnership as we advance our pipeline of oral biologic therapies aimed at addressing the needs of patients with chronic diseases. Additionally, at ENDO 2025, we presented compelling preclinical data on our oral bispecific GLP-1/GLP-2 receptor agonist, RT-114. This data, demonstrating bioequivalence to subcutaneous i...